Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Newbury Pharmaceuticals AB's Days Sales Outstanding for the
three
months ended in Feb. 2026 was 0.
Newbury Pharmaceuticals AB's Days Inventory for the
three
months ended in Feb. 2026 was 166.89.
Newbury Pharmaceuticals AB's Days Payable for the
three
months ended in Feb. 2026 was 0.
Therefore, Newbury Pharmaceuticals AB's Cash Conversion Cycle (CCC) for the
three
months ended in Feb. 2026 was 166.89.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Newbury Pharmaceuticals AB Cash Conversion Cycle Related Terms
Newbury Pharmaceuticals AB Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB Cash Conversion Cycle Chart
OSTO:NEWBRY vs ZTS, UTHR, VTRS: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Newbury Pharmaceuticals AB's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Newbury Pharmaceuticals AB Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Newbury Pharmaceuticals AB's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Newbury Pharmaceuticals AB's Cash Conversion Cycle falls into.
Newbury Pharmaceuticals AB Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Newbury Pharmaceuticals AB's Cash Conversion Cycle for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Newbury Pharmaceuticals AB (OSTO:NEWBRY) has a Cash Conversion Cycle of 166.89 as of Feb. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Newbury Pharmaceuticals AB and its competitors.
Is Newbury Pharmaceuticals AB's Cash Conversion Cycle too high?
Newbury Pharmaceuticals AB's current Cash Conversion Cycle is 166.89. The Drug Manufacturers industry median Cash Conversion Cycle is 145.69. Newbury Pharmaceuticals AB's value of 166.89 is 14.6% above this industry median. Overall, Newbury Pharmaceuticals AB has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Newbury Pharmaceuticals AB's Cash Conversion Cycle compare to ZTS and UTHR?
Newbury Pharmaceuticals AB's Cash Conversion Cycle of 166.89 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.69. Newbury Pharmaceuticals AB's value of 166.89 is 14.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.69, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Newbury Pharmaceuticals AB's current Cash Conversion Cycle of 166.89 is 14.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Newbury Pharmaceuticals AB and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Newbury Pharmaceuticals AB's current Cash Conversion Cycle is 166.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newbury Pharmaceuticals AB stock overvalued right now?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB (OSTO:NEWBRY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr3.20, compared to a current price of kr2.48 — trading 22.5% below its estimated fair value. The current Cash Conversion Cycle is 166.89 and 14.6% above the Drug Manufacturers industry median of 145.69. Newbury Pharmaceuticals AB's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Newbury Pharmaceuticals AB (OSTO:NEWBRY), the current Cash Conversion Cycle is 166.89 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Newbury Pharmaceuticals AB (OSTO:NEWBRY) Overvalued in 2026?
Based on GuruFocus' analysis, Newbury Pharmaceuticals AB stock appears to be undervalued.
The current stock price of kr2.48 is trading 22.5% below its estimated GF Value™ of kr3.20.
GuruFocus considers Newbury Pharmaceuticals AB to be Modestly Undervalued.
Key valuation signals for OSTO:NEWBRY:
Cash Conversion Cycle: 166.89
GF Value™: kr3.20 vs. price of kr2.48 (22.5% below fair value)
Industry Position: 14.6% above the Drug Manufacturers median
No single metric tells the full story. See the OSTO:NEWBRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Newbury Pharmaceuticals AB is a hybrid pharmaceutical company for specialty prescription drugs, innovation and brands with focus on the Scandinavian markets.
41GF Score
Get the complete analysis for OSTO:NEWBRY
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:NEWBRY has been successfully added to your 
